|
MechanismAPOC3 inhibitors |
|
|
|
|
Drug Highest PhasePhase 2 |
First Approval Ctry. / Loc.- |
First Approval Date- |
一项评估RBD5044在中国高甘油三酯血症参与者中的疗效和安全性的多中心、随机、双盲、安慰剂对照II期临床研究
[Translation] A multicenter, randomized, double-blind, placebo-controlled phase II clinical trial evaluating the efficacy and safety of RBD5044 in Chinese participants with hypertriglyceridemia.
主要目的:评价RBD5044在高甘油三酯血症参与者中降低空腹血清甘油三酯(TG)的疗效。
[Translation] Primary objective: To evaluate the efficacy of RBD5044 in reducing fasting serum triglycerides (TG) in participants with hypertriglyceridemia.
100 Clinical Results associated with Ruibotech (Shandong) Biomedical Technology Co., Ltd.
0 Patents (Medical) associated with Ruibotech (Shandong) Biomedical Technology Co., Ltd.
100 Deals associated with Ruibotech (Shandong) Biomedical Technology Co., Ltd.
100 Translational Medicine associated with Ruibotech (Shandong) Biomedical Technology Co., Ltd.